These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33119613)

  • 1. Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
    Strayer DR; Young D; Mitchell WM
    PLoS One; 2020; 15(10):e0240403. PubMed ID: 33119613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
    Strayer DR; Carter WA; Stouch BC; Stevens SR; Bateman L; Cimoch PJ; Lapp CW; Peterson DL; ; Mitchell WM
    PLoS One; 2012; 7(3):e31334. PubMed ID: 22431963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).
    Mitchell WM
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):755-70. PubMed ID: 27045557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.
    Smith ME; Haney E; McDonagh M; Pappas M; Daeges M; Wasson N; Fu R; Nelson HD
    Ann Intern Med; 2015 Jun; 162(12):841-50. PubMed ID: 26075755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome.
    Morris MC; Cooney KE; Sedghamiz H; Abreu M; Collado F; Balbin EG; Craddock TJA; Klimas NG; Broderick G; Fletcher MA
    Clin Ther; 2019 Apr; 41(4):656-674.e4. PubMed ID: 30929860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.
    Castro-Marrero J; Sáez-Francàs N; Santillo D; Alegre J
    Br J Pharmacol; 2017 Mar; 174(5):345-369. PubMed ID: 28052319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
    Castro-Marrero J; Segundo MJ; Lacasa M; Martinez-Martinez A; Sentañes RS; Alegre-Martin J
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.
    Cash A; Kaufman DL
    J Transl Med; 2022 Jun; 20(1):295. PubMed ID: 35764955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome.
    Strayer DR; Carter WA; Brodsky I; Cheney P; Peterson D; Salvato P; Thompson C; Loveless M; Shapiro DE; Elsasser W
    Clin Infect Dis; 1994 Jan; 18 Suppl 1():S88-95. PubMed ID: 8148460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
    Smith MEB; Nelson HD; Haney E; Pappas M; Daeges M; Wasson N; McDonagh M
    Evid Rep Technol Assess (Full Rep); 2014 Dec; (219):1-433. PubMed ID: 30313001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Fluge Ø; Rekeland IG; Lien K; Thürmer H; Borchgrevink PC; Schäfer C; Sørland K; Aßmus J; Ktoridou-Valen I; Herder I; Gotaas ME; Kvammen Ø; Baranowska KA; Bohnen LMLJ; Martinsen SS; Lonar AE; Solvang AH; Gya AES; Bruland O; Risa K; Alme K; Dahl O; Mella O
    Ann Intern Med; 2019 May; 170(9):585-593. PubMed ID: 30934066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine.
    Joseph P; Pari R; Miller S; Warren A; Stovall MC; Squires J; Chang CJ; Xiao W; Waxman AB; Systrom DM
    Chest; 2022 Nov; 162(5):1116-1126. PubMed ID: 35526605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term neuromuscular consequences of SARS-Cov-2 and their similarities with myalgic encephalomyelitis/chronic fatigue syndrome: results of the retrospective CoLGEM study.
    Retornaz F; Rebaudet S; Stavris C; Jammes Y
    J Transl Med; 2022 Sep; 20(1):429. PubMed ID: 36153556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the effectiveness and cost-effectiveness of FITNET-NHS (Fatigue In Teenagers on the interNET in the NHS) compared to Activity Management to treat paediatric chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (ME): protocol for a randomised controlled trial.
    Baos S; Brigden A; Anderson E; Hollingworth W; Price S; Mills N; Beasant L; Gaunt D; Garfield K; Metcalfe C; Parslow R; Downing H; Kessler D; Macleod J; Stallard P; Knoop H; Van de Putte E; Nijhof S; Bleijenberg G; Crawley E
    Trials; 2018 Feb; 19(1):136. PubMed ID: 29471861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
    Fluge Ø; Risa K; Lunde S; Alme K; Rekeland IG; Sapkota D; Kristoffersen EK; Sørland K; Bruland O; Dahl O; Mella O
    PLoS One; 2015; 10(7):e0129898. PubMed ID: 26132314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.
    Chung S; Ben-Menachem E; Sperling MR; Rosenfeld W; Fountain NB; Benbadis S; Hebert D; Isojärvi J; Doty P
    CNS Drugs; 2010 Dec; 24(12):1041-54. PubMed ID: 21090838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome.
    Suhadolnik RJ; Reichenbach NL; Hitzges P; Adelson ME; Peterson DL; Cheney P; Salvato P; Thompson C; Loveless M; Müller WE
    In Vivo; 1994; 8(4):599-604. PubMed ID: 7893988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of SARS-CoV-2 Seropositivity With Myalgic Encephalomyelitis and/or Chronic Fatigue Syndrome Among Children and Adolescents in Germany.
    Sorg AL; Becht S; Jank M; Armann J; von Both U; Hufnagel M; Lander F; Liese JG; Niehues T; Verjans E; Wetzke M; Stojanov S; Behrends U; Drosten C; Schroten H; von Kries R
    JAMA Netw Open; 2022 Sep; 5(9):e2233454. PubMed ID: 36166227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatched double-stranded RNA: polyI:polyC12U.
    Adis Editorial
    Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.